Clozapine and COVID-19

Clozapine and COVID-19

J Psychiatry Neurosci 2020;45(4):E1 | PDF

Gary Remington, MD, PhD; Valerie Powell, RN, BScN

Affiliations: From the Centre of Addiction and Mental Health (CAMH) (Remington, Powell); the Campbell Family Mental Health Research Institute, CAMH (Remington); the Department of Psychiatry, University of Toronto (Remington); and the Graduate Department of Psychological Clinical Science, University of Toronto– Scarborough (Remington), Toronto, Ont., Canada.

Competing interests: G. Remington has received clinical, research and advisory board support from HLS Therapeutics, consultant fees from Mitsubishi-Tanabe Pharma Corporation, and research support from the University of Toronto, Canadian Institutes of Health Research (CIHR) and Research Hospital Fund–Canada Foundation for Innovation (RHF-CFI). No other competing interests were declared.

DOI: 10.1503/jpn.2045301